ACIU

About AC Immune SA (ACIU) Stock

AC Immune SA (ACIU) closed the 2026-09-16 session at $2.63, down 1.68% versus the previous close (-0.05). The stock opened at $2.68 and traded between $2.63 and $2.73 during that session. Session trading volume was 68K shares. The volume-weighted average price (VWAP) is $2.69.

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

AC Immune SA has a market capitalization of $266.5 million. ACIU is listed on the XNAS exchange. The company employs approximately 122 people. The recorded listing date is 2016-09-23.

On this page you can find market ACIU stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors.